JNJ · Johnson & Johnson

Track JNJ — free Ask ALVIS about JNJ

$256.35 +0.53 (+0.21%) At close · Jul 31

Market Cap

$616.50B

2.41B

Up next

Next earnings call

Oct 14, 2026 Est · unconfirmed · in 11 wks

FQ3-27 quarter ends

~Oct 3, 2026 Est

Latest filing: 10-Q

filed Jul 23, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Ask ALVIS about this →

Equibles Research

our published analysis of this company

Research Thesis July 31, 2026

Novo Nordisk's 1.3 million Wegovy pill TRxs meet a 50% WAC cut — and the bear case still wins

Novo Nordisk is the only name in the GLP-1 bellwether set guiding negative adjusted-sales growth for 2026 (-4% to -12% at CER), even as Wegovy pill TRxs hit around 1.3 million in Q1 2026 and the 1 January 2027 WAC reset to USD 675 locks in further realised-price compression.

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very Low

Market backdrop VIX 16 · calm Equity put/call 0.61

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +13%

above

Price vs 50-day avg +5%

above

RSI (14) 52

neutral

MACD trend Negative

52-week position 84%

mid-range

Volume (OBV) Bullish div.

accumulating

Momentum

relative strength

Strong

1-month return −3%

trailing

6-month return +7%

trailing

YTD return +25%

this year

Relative strength −1%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $245 › 200d $226 — 50d above 200d

Institutional flow Accumulating

2,281 of 4,635 funds reported for Jun 30 · net +3.2M sh shares · +88 new

Insider flow Distributing

Net -$8.2M over 90 days · 100% sells

Short interest Rising

1.14% of float · ▲ +3.2% MoM · 3.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

4,635 holders — near 3-yr high, broad support

Squeeze score 54

elevated · 0–100

Fundamentals

Strong

Revenue growth +6%

Y/Y

Gross margin 68%

contracting

EPS growth +91%

Y/Y

Free cash flow $19.7B

Valuation P/E 29.7

in line

Buyback $5.0B

authorized

Balance sheet $28.2B

net debt

Quant / Vol

risk profile

Very Low

Volatility 18%

annualized · 1-yr

Max drawdown −11%

past year

ATR 2.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 0 of last 2

Latest guidance · from the 8-K filed Jul 15, 2026

Adjusted Operational Sales Change vs. Prior Year · Full-year 2026 Non-GAAP Initiated 6.2% – 6.8%

Operational Sales · Full-year 2026 Non-GAAP Raised $100.3B – $100.9B

Operational Sales Change vs. Prior Year · Full-year 2026 Non-GAAP Initiated 6.5% – 7.1%

Estimated Reported Sales · Full-year 2026 Raised $100.8B – $101.4B

prior FY $94.19B midpoint +7.3% Y/Y

Adjusted Operational EPS (Diluted) · Full-year 2026 Non-GAAP Raised $11.50 – $11.65

Estimated Reported Sales Change vs. Prior Year · Full-year 2026 Initiated 7% – 7.6%

Adjusted Operational EPS (Diluted) Change vs. Prior Year · Full-year 2026 Non-GAAP Initiated 6.6% – 8%

Adjusted EPS (Diluted) Change vs. Prior Year · Full-year 2026 Non-GAAP Initiated 7.5% – 8.9%

Adjusted EPS (Diluted) · Full-year 2026 Non-GAAP Raised $11.60 – $11.75

Guided vs delivered · last 2 settled

Guidance full year 2026

guided $11.30 – $11.50

guided $11.30 – $11.50 $11.03 Miss −3.2%

Reported sales 2026

guided $100.5B

guided $100.5B $94.19B Miss −6.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+13% Bullish

Price vs 50-day avg

+5% Bullish

RSI (14)

52 Neutral

MACD trend

Negative Bearish

52-week position

84% Neutral

Volume (OBV)

Bullish div. Bullish

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $245 › 200d $226 — 50d above 200d

Institutional flow Accumulating

2,281 of 4,635 funds reported for Jun 30 · net +3.2M sh shares · +88 new

Insider flow Distributing

Net -$8.2M over 90 days · 100% sells

Short interest Rising

1.14% of float · ▲ +3.2% MoM · 3.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

4,635 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $161 Now $256 · 84% 52-wk high $275

vs 200-day avg +13% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Free Cash Flow non-GAAP	$8,700M	Q2	—

Adjusted Operational Sales non-GAAP	6.1%	Q4 2025	—
Operational Sales non-GAAP	7.1%	Q4 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Drug Manufacturers - General — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
JNJ Johnson & Johnson this stock	$616.50B	+24.5%	+6.0%	29.7	1.1%
LLY ELI LILLY & Co	$1.08T	+7.1%	+44.7%	40.8	1.1%
ABBV AbbVie Inc.	$454.79B	+10.7%	+8.6%	126.8	1.3%
MRK Merck & Co., Inc.	$320.56B	+25.5%	+1.4%	36.6	1.2%
NVS Novartis AG	$296.80B	+16.7%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

4,689

% held: 72.3%
Reported: 2,281 of 4,635
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

1,594

View

Short & Settlement

Short Interest Rising

Shares short

27.4M

Days to cover: 3.7d
Change: +848.5K sh

View

Short Volume

Short vol %

55%

As of: Jul 31, 2026

Short Total

View

Fails to Deliver

FTD shares

4.0K

Value: $1.0M
As of: Jul 13, 2026

View

Off-Exchange

Off-exchange %

46.0%

Week of: Jul 6, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$8.2M

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Congressional Trades Sell

Member

Thomas H. Kean

Amount: $1.0K–$15.0K
Traded: Jun 29, 2026

View

Financials

Revenue (FY)

$94.2B

Net income (FY): $26.8B
EPS diluted: $11.03

View

Buybacks

Authorized

$5.0B

View

Filings

SEC Filings

Latest

8-K

Filed: Jul 29, 2026
This year: 10

View

Proposed Sales

Value

$5.8M

Shares: 23.1K
Filed: Jul 20, 2026

View

Earnings & Events

Earnings Calls

Last call

Jul 15, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
JNJ	-2.7%	-2.5%	+7.4%	+0.9%	+24.5%
SPY	+1.1%	+0.3%	+8.2%	+0.0%	+9.6%
vs SPY	-3.8%	-2.8%	-0.8%	+0.9%	+15.0%

Capital returns

Latest dividend

$1.34 / share · ex May 26, 2026

Raised 3.1%

Paid (TTM)

$5.24 / share · 4 payouts

Dividend yield (TTM, derived)

2.04%

Buyback program · as of Sep 14, 2022

Authorized

$5.00B

Spent (derived)

—

Remaining

—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 200406 CUSIP 478160104 13F (30d) 2292 filings 2245 filers Visit website Investor relations

JNJ · Johnson & Johnson

Price & Indicators

Up next

AI Brief

Equibles Research

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance

Capital returns